- Sanofi SA (NASDAQ:SNY) has agreed to acquire Provention Bio Inc (NASDAQ:PRVB) for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.
- The transaction adds a type 1 diabetes therapy to Sanofi’s core asset portfolio in General Medicines, and further drives its strategic shift toward products with a differentiated profile.
- In November 2022, the FDA approved Tzield (teplizumab-mzwv) to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years and older with stage 2 type 1 diabetes.
- The purchase builds on an existing co-promotion agreement with Provention Bio, already delivering Tzield to patients needing this immune-mediated therapy.
- Tzield is also in late-stage clinical development for pediatric and adolescent patients newly diagnosed with clinical T1D (Stage 3).
- A Phase 3 trial, PROTECT, is underway, and top-line results are expected in the second half of 2023.
- Additional opportunities for TZIELD include re-dosing and formulations and new therapeutic indications.
- Sanofi currently expects to complete the acquisition in the second quarter of 2023.
- Price Action: PRVB shares are up 257.90% at $23.98 on the last check Monday.
Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% in 2023. Here’s Why.
So far, 2023 has not started well for the hedge fund sector, as a common SPDR S&P 500 Trust ETF (ARCA: SPY) fared much better than the Global X Guru Index ETF (ARCA: GURU), a fund that invests in the highest conviction ideas from a chosen pool of hedge funds.
